Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

A Study of Tolerability, Satisfaction, and Cost Reduction Using a 10% Immunoglobulin Product at Higher Administration Rates

Bauer, Susan BSN, RN, CRNI®, VA-BC; Fadeyi, Michael PharmD, MS; Chan, Sheryl RPH

doi: 10.1097/NAN.0000000000000347
Features
Buy

Gammaplex 10% (immune globulin intravenous [human], Bio Products Laboratory, Ltd) can be administered with a 15-minute rate-escalation protocol. This analysis examined safety, patient satisfaction, and cost savings in 49 patients administered Gammaplex 10% via rapid infusion over 11 months. Fourteen patients reported 38 adverse reactions, 37 of which were deemed minor/moderate. Patient satisfaction was very good/outstanding. Infusions were estimated to be 2.4 hours shorter than previously administered intravenous immunoglobulin infusions, saving $151.61 per visit in nursing costs. Rapid infusion of Gammaplex 10% was found to be a safe option to reduce the costs of intravenous immunoglobulin treatment while maintaining patient satisfaction.

American Outcomes Management, LP, Fort Worth, Texas.

Susan Bauer, BSN, RN, CRNI®, VA-BC, is director of patient services for American Outcomes Management. She has been employed in the home infusion industry for the past 30 years and has 20 years of experience with patients requiring immune globulin therapies.

Michael Fadeyi, PharmD, MS, is the chief pharmacy officer for American Outcomes Management. He has more than 30 years' pharmacy experience (both academic and home infusion). Dr Fadeyi has published numerous journal articles pertaining to the home infusion industry.

Sheryl Chan, RPH, is director of pharmacy for the New York branch of American Outcomes Management. She has been employed in the home infusion industry for the past 24 years.

Corresponding Author: Susan Bauer, BSN, RN, CRNI®, VA-BC, American Outcomes Management, LP, 1 Crosfield Avenue, Suite 304, West Nyack, NY 10994 (sbauer@aomofny.com).

All authors of this article are employees of American Outcomes Management, LP, which financially supported this study. Funding for this manuscript was provided by Bio Products Laboratory, Ltd, Elstree, United Kingdom.

© Copyright 2019 by Infusion Nurses Society